1. Metabolic Enzyme/Protease
  2. Tryptophan Hydroxylase

LX1606 Hippurate (Synonyms: Telotristat etiprate; LX 1606 Hippurate; LX-1606 Hippurate)

Cat. No.: HY-13055
Handling Instructions

LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.

For research use only. We do not sell to patients.
LX1606 Hippurate Chemical Structure

LX1606 Hippurate Chemical Structure

CAS No. : 1137608-69-5

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $199 In-stock
5 mg $130 In-stock
10 mg $240 In-stock
50 mg $800 In-stock
100 mg $1400 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of LX1606 Hippurate:

Top Publications Citing Use of Products

Featured Recommendations

Related Screening Libraries:

Related Small Molecules:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. IC50 Value: Target: Tryptophan hydroxylase in vitro: in vivo: LX1606 (LX 1606, LX-1606) is useful for Neurological Diseas [1]. LX1606 were given orally to mice. LX1606 reduced 5-HT significantly in the gut and blood but not in the brain. oral LX1032 reduced the severity of TNBS-induced colitis; the expression of 24% of 84 genes encoding inflammation-related cytokines and chemokines was lowered at least fourfold and the reduced expression of 17% was statistically significant [1]. Treatment with LX1606 showed a strong positive effect in ameliorating TNBS-induced IBD in mice as assessed by various parameters of disease development. These preclinical data demonstrate that inhibition of TPH activity by LX1606 may provide a new approach for the treatment of IBD and its serotonin-mediated symptoms[3].

Clinical Trial
Sponsor Condition Start Date Phase
Lexicon Pharmaceuticals Inc Carcinoid syndrome 2012-10-31 Phase 3
Lexicon Pharmaceuticals Inc Carcinoid syndrome 2009-03-31 Phase 2
Lexicon Pharmaceuticals Inc Ulcerative colitis 2011-12-31 Phase 2
Lexicon Pharmaceuticals Inc Carcinoid syndrome 2010-05-31 Phase 2
Lexicon Pharmaceuticals Inc 2013-08-31 Phase 1
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.3260 mL 6.6300 mL 13.2600 mL
5 mM 0.2652 mL 1.3260 mL 2.6520 mL
10 mM 0.1326 mL 0.6630 mL 1.3260 mL
M.Wt

754.15

Formula

C₃₆H₃₅ClF₃N₇O₆

CAS No.

1137608-69-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 28 mg/mL

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LX1606 Hippurate
Cat. No.:
HY-13055
Quantity: